TRE-515 with lutetium Lu 177 vipivotide tetraxetan (Pluvicto): FDA status

Breakthrough designation Indication: Metastatic castration resistant prostate cancer. Company: Telix Pharmaceuticals.

Regulatory history

All products in the FDA Tracker

Loading today's edition…